These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Assessment of an altered E1B promoter on the specificity and potency of triple-regulated conditionally replicating adenoviruses: implications for the generation of ideal m-CRAs. Horikawa Y; Wang Y; Nagano S; Kamizono J; Ikeda M; Komiya S; Kosai KI Cancer Gene Ther; 2011 Oct; 18(10):724-33. PubMed ID: 21836631 [TBL] [Abstract][Full Text] [Related]
4. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145 [TBL] [Abstract][Full Text] [Related]
5. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Ahmed A; Jevremovic D; Suzuki K; Kottke T; Thompson J; Emery S; Harrington K; Bateman A; Vile R Gene Ther; 2003 Sep; 10(19):1663-71. PubMed ID: 12923565 [TBL] [Abstract][Full Text] [Related]
6. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599 [TBL] [Abstract][Full Text] [Related]
7. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558 [TBL] [Abstract][Full Text] [Related]
16. [Construction of a plasmid vector of fused protein genes driven by human insulin-like growth factor II P3 promoter]. Zhou HK; Yang DH; Tang SH; Huang W; Lu XH Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(2):106-10. PubMed ID: 16620715 [TBL] [Abstract][Full Text] [Related]
17. A simple method for the simultaneous detection of E1A and E1B in adenovirus stocks. Suzuki E; Murata T; Watanabe S; Kujime Y; Hirose M; Pan J; Yamazaki T; Ugai H; Yokoyama KK Oncol Rep; 2004 Jan; 11(1):173-8. PubMed ID: 14654922 [TBL] [Abstract][Full Text] [Related]
18. Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses. Hurtado Picó A; Wang X; Sipo I; Siemetzki U; Eberle J; Poller W; Fechner H Mol Ther; 2005 Apr; 11(4):563-77. PubMed ID: 15771959 [TBL] [Abstract][Full Text] [Related]
19. A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication. Fechner H; Wang X; Picó AH; Wildner J; Suckau L; Pinkert S; Sipo I; Weger S; Poller W J Biotechnol; 2007 Jan; 127(4):560-74. PubMed ID: 17083991 [TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Hannay J; Davis JJ; Yu D; Liu J; Fang B; Pollock RE; Lev D Gene Ther; 2007 Apr; 14(8):671-81. PubMed ID: 17287860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]